• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Caspase-1 activation, IL-1/IL-6 signature and IFNγ-induced chemokines in lungs of COVID-19 patients

tetano

Editor, Senior Moderator
Front Immunol


. 2025 Jan 15:15:1493306.
doi: 10.3389/fimmu.2024.1493306. eCollection 2024. Caspase-1 activation, IL-1/IL-6 signature and IFNγ-induced chemokines in lungs of COVID-19 patients

Audrey Cambon[SUP] 1 [/SUP], Christophe Guervilly[SUP] 2 3 [/SUP], Clémence Delteil[SUP] 4 [/SUP], Nicola Potere[SUP] 5 [/SUP], Richard Bachelier[SUP] 1 [/SUP], Edwige Tellier[SUP] 1 [/SUP], Evelyne Abdili[SUP] 1 6 [/SUP], Marine Leprince[SUP] 7 [/SUP], Marco Giani[SUP] 5 [/SUP], Ildo Polidoro[SUP] 8 [/SUP], Valentina Albanese[SUP] 8 [/SUP], Paolo Ferrante[SUP] 8 [/SUP], Laurence Coffin[SUP] 9 [/SUP], Michael Schiffrin[SUP] 9 [/SUP], Laurent Arnaud[SUP] 6 [/SUP], Romaric Lacroix[SUP] 1 6 [/SUP], Sandrine Roque[SUP] 7 [/SUP], Jean-Marie Forel[SUP] 2 3 [/SUP], Sami Hraiech[SUP] 2 3 [/SUP], Laurent Daniel[SUP] 10 [/SUP], Laurent Papazian[SUP] 11 [/SUP], Françoise Dignat-George[SUP] 1 6 [/SUP], Gilles Kaplanski[SUP] 1 7 [/SUP]



Affiliations
Abstract

Rationale: COVID-19-associated acute-respiratory distress syndrome (C-ARDS) results from a direct viral injury associated with host excessive innate immune response mainly affecting the lungs. However, cytokine profile in the lung compartment of C-ARDS patients has not been widely studied, nor compared to non-COVID related ARDS (NC-ARDS).
Objectives: To evaluate caspase-1 activation, IL-1 signature, and other inflammatory cytokine pathways associated with tissue damage using post-mortem lung tissues, bronchoalveolar lavage fluids (BALF), and serum across the spectrum of COVID-19 severity.
Methods: Histological features were described and activated-caspase-1 labeling was performed in 40 post-mortem biopsies. Inflammatory cytokines were quantified in BALF and serum from 19 steroid-treated-C-ARDSand compared to 19 NC-ARDS. Cytokine concentrations were also measured in serum from 128 COVID-19 patients at different severity stages.
Measurements and main results: Typical "diffuse alveolar damage" in lung biopsies were associated with activated caspase-1 expression and vascular lesions. Soluble Caspase-1p20, IL-1β, IL-1Ra, IL-6 and at lower level IFNγ and CXCL-10, were highly elevated in BALF from steroid-treated-C-ARDS as well as in NC-ARDS. IL-1β appeared concentrated in BALF, whereas circulating IL-6 and IL-1Ra concentrations were comparable to those in BALF and correlated with severity. TNFα, TNFR1 and CXCL8 however, were significantly higher in NC-ARDS compared to C-ARDS, treated by steroid.
Conclusions: In the lungs of C-ARDS, both caspase-1 activation with a predominant IL-1β/IL-6 signature and IFNγ -associated chemokines are elevated despite steroid treatment. These pathways may be specifically targeted in ARDS to improve response to treatment and to limit alveolar and vascular lung damage.

Keywords: COVID-19; acute respiratory distress syndrome; bronchoalveolar fluid; caspase-1; cytokines; vasculopathy.

 
Back
Top Bottom